TFF Pharmaceuticals announced that it will study the feasibility of formulating Emory University's mRNA-based Cas13a antiviral for the treatment of SARS-CoV-2 and influenza A and B as a dry powder using the company's thin film freezing technology. Funding for the study is provided by the Biomedical Advanced Research and Development Authority (BARDA) as part of its … [Read more...] about TFF Pharmaceuticals partners with Emory University on mRNA-based antiviral DPI with BARDA funding
Medical
Roivant’s Pulmovant subsidiary developing mosliciguat DPI licensed from Bayer for the treatment of PH-ILD
Roivant has revealed that its Pulmovant subsidiary is developing inhaled dry powder mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), and Pulmovant presented a poster with data from the Phase 1b ATMOS study of mosliciguat at the 2024 ERS Congress. Roivant says that it paid approximately $14 million up front … [Read more...] about Roivant’s Pulmovant subsidiary developing mosliciguat DPI licensed from Bayer for the treatment of PH-ILD
Ji Xing’s Chinese Phase 3 trial of Milestone’s etripamil nasal spray meets primary endpoint
According to Milestone Pharmaceuticals, a Phase 3 trial of etripamil nasal spray in patients with paroxysmal supraventricular tachycardia (PSVT) that was conducted by Ji Xing Pharmaceuticals in China met its primary endpoint of the proportion of patients converting to sinus rhythm within 30 minutes post-dose. Ji Xing acquired the Chinese rights to etripamil for PVST … [Read more...] about Ji Xing’s Chinese Phase 3 trial of Milestone’s etripamil nasal spray meets primary endpoint
ENA Respiratory gets additional funding from the US Department of Defense for development of INNA-051 intranasal antiviral
ENA Respiratory announced that it has received a contract extension from the US Department of Defense (DoD), providing additional funds for continued development of INNA-051, a dry powder intranasal TLR2/6 agonist. In January 2023, ENA Respiratory announced that the DoD had provided funding to develop a dry powder formulation of the antiviral, which had previously … [Read more...] about ENA Respiratory gets additional funding from the US Department of Defense for development of INNA-051 intranasal antiviral
Avalyn iniates Phase 2b MIST study of AP01 inhaled pirfenidone in PPF patients
Avalyn Pharma has announced the initiation of the Phase 2b MIST study of AP01 pirfenidone inhalation solution in patients with progressive pulmonary fibrosis (PPF). In March 2023, the company announced that a Phase 1b trial of nebulized AP01 in IPF patients demonstrated a significant reduction in the progression of the disease, with lung function in most patients … [Read more...] about Avalyn iniates Phase 2b MIST study of AP01 inhaled pirfenidone in PPF patients
ENA Respiratory announces advancement into Phase 1b study of INNA-051 intranasal dry powder antiviral
ENA Respiratory announced that it has completed a Phase 1a study and has initiated a Phase 1b study of its INNA-051 TLR2/6 agonist pan-viral nasal powder in people aged 60 and older. Earlier this year, the company announced that the FDA had cleared an IND for the Phase 1b trial. According to the company, the new trial is expected to enroll up to 40 … [Read more...] about ENA Respiratory announces advancement into Phase 1b study of INNA-051 intranasal dry powder antiviral
Avalyn initiates Phase 1b study of APO2 inhaled nintedanib
Avalyn Pharma has initiated a Phase 1b SAD/MAD trial of its AP02 inhaled nintedanib delivered via the PARI eFlow nebulizer in healthy adults, the company said. Avalyn is developing AP02, along with AP01 inhaled pirfenidone, for the treatment of pulmonary fibrosis. In September 2023, the company announced that it had raised $175 million for continued development of … [Read more...] about Avalyn initiates Phase 1b study of APO2 inhaled nintedanib
Oragenics says pre-clinical study demonstrated that ONP-002 intranasal dry powder likely has a large cardiac safety margin
Oragenics announced that a GLP human Ether-à-go-go-Related Gene study conducted by Charles River Laboratories found that ONP-002, an intranasal neurosteroid, would likely not cause heart arrhythmias. ONP-002 is a new chemical entity formulated as a dry powder and delivered via a breath-activated nasal delivery device. The nasal powder is in development for the … [Read more...] about Oragenics says pre-clinical study demonstrated that ONP-002 intranasal dry powder likely has a large cardiac safety margin
Nasus Pharma says its FMXIN002 intranasal dry powder epinephrine demonstrated 5 years stability
According to Nasus Pharma, a stability study of the company's FMXIN002 nasal epinephrine powder demonstrated full stability for the formulation and device over 5 years of storage at 15 to 25℃. The company said that at 5 years, the epinephrine level was at 97.5%, with degradation products at 0.37%. Nasus noted that a previous stability test at 40℃ and 75% humidity … [Read more...] about Nasus Pharma says its FMXIN002 intranasal dry powder epinephrine demonstrated 5 years stability
NeOnc initiates Phase 2 trial of NEO100 intranasal perillyl alcohol in patients with high-grade meningiomas
NeOnc Technologies has announced the initiation of a Phase 2 trial of NEO100 intranasal perillyl alcohol in patients with tumors of the membranes surrounding the brain and/or spinal cord. A Phase 2 trial of the intranasal formulation in patients with grade 4 gliomas was initiated in May 2016 and recently expanded to include patients with a type of astrocytoma. Two … [Read more...] about NeOnc initiates Phase 2 trial of NEO100 intranasal perillyl alcohol in patients with high-grade meningiomas